These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2571412)

  • 21. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth state-dependent regulation of protein kinase C in normal and transformed murine cells.
    McCaffrey PG; Rosner MR
    Cancer Res; 1987 Feb; 47(4):1081-6. PubMed ID: 3492269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracellular signal regulated kinase 5 mediates signals triggered by the novel tumor promoter palytoxin.
    Charlson AT; Zeliadt NA; Wattenberg EV
    Toxicol Appl Pharmacol; 2009 Dec; 241(2):143-53. PubMed ID: 19716839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice.
    Xian W; Kiguchi K; Imamoto A; Rupp T; Zilberstein A; DiGiovanni J
    Cell Growth Differ; 1995 Nov; 6(11):1447-55. PubMed ID: 8562483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of aplysiatoxin, debromoaplysiatoxin, and teleocidin on receptor binding and phospholipid metabolism.
    Horowitz AD; Fujiki H; Weinstein IB; Jeffrey A; Okin E; Moore RE; Sugimura T
    Cancer Res; 1983 Apr; 43(4):1529-35. PubMed ID: 6299522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of palytoxin-induced channels in mouse neuroblastoma cells.
    Rouzaire-Dubois B; Dubois JM
    Toxicon; 1990; 28(10):1147-58. PubMed ID: 1702238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
    Huang JS; Nishimura J; Huang SS; Deuel TF
    J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palytoxin-induced effects on partial reactions of the Na,K-ATPase.
    Harmel N; Apell HJ
    J Gen Physiol; 2006 Jul; 128(1):103-18. PubMed ID: 16801384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis.
    Wattenberg EV
    Am J Physiol Cell Physiol; 2007 Jan; 292(1):C24-32. PubMed ID: 16855216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulation of arachidonic acid metabolism by different types of tumor promoters.
    Levine L; Fujiki H
    Carcinogenesis; 1985 Nov; 6(11):1631-4. PubMed ID: 2865014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of protein kinase signaling cascades by palytoxin.
    Wattenberg EV
    Toxicon; 2011 Mar; 57(3):440-8. PubMed ID: 21070801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palytoxin acts through Na+,K+-ATPase.
    Habermann E
    Toxicon; 1989; 27(11):1171-87. PubMed ID: 2575806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of apical vs. basolateral palytoxin on LLC-PK1 renal epithelia.
    Mullin JM; Snock KV; McGinn MT
    Am J Physiol; 1991 Jun; 260(6 Pt 1):C1201-11. PubMed ID: 1676241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulation of superoxide anion formation by the non-TPA type tumor promoters palytoxin and thapsigargin in porcine and human neutrophils.
    Kano S; Iizuka T; Ishimura Y; Fujiki H; Sugimura T
    Biochem Biophys Res Commun; 1987 Mar; 143(2):672-7. PubMed ID: 2882751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.
    Bignami GS; Senter PD; Grothaus PG; Fischer KJ; Humphreys T; Wallace PM
    Cancer Res; 1992 Oct; 52(20):5759-64. PubMed ID: 1356620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palytoxin acidifies chick cardiac cells and activates the Na+/H+ antiporter.
    Frelin C; Vigne P; Breittmayer JP
    FEBS Lett; 1990 May; 264(1):63-6. PubMed ID: 1970964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A radioimmunoassay for palytoxin.
    Levine L; Fujiki H; Gjika HB; Van Vunakis H
    Toxicon; 1988; 26(12):1115-21. PubMed ID: 2907189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in erythrocyte permeability due to palytoxin as compared to amphotericin B.
    Ahnert-Hilger G; Chhatwal GS; Hessler HJ; Habermann E
    Biochim Biophys Acta; 1982 Jun; 688(2):486-94. PubMed ID: 6125212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.